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Abstract: By way of a Next-Generation Sequencing NGS high throughput approach, we defined the
mutational profile in a cohort of 221 normal karyotype acute myeloid leukemia (NK-AML) enrolled
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into a prospective randomized clinical trial, designed to evaluate an intensified chemotherapy
program for remission induction. NPM1, DNMT3A, and FLT3-ITD were the most frequently mutated
genes while DNMT3A, FLT3, IDH1, PTPN11, and RAD21 mutations were more common in the NPM1
mutated patients (p < 0.05). IDH1 R132H mutation was strictly associated with NPM1 mutation
and mutually exclusive with RUNX1 and ASXL1. In the whole cohort of NK-AML, no matter the
induction chemotherapy used, by multivariate analysis, the achievement of complete remission
was negatively affected by the SRSF2 mutation. Alterations of FLT3 (FLT3-ITD) and U2AF1 were
associated with a worse overall and disease-free survival (p < 0.05). FLT3-ITD positive patients who
proceeded to alloHSCT had a survival probability similar to FLT3-ITD negative patients and the
transplant outcome was no different when comparing high and low-AR-FLT3-ITD subgroups in
terms of both OS and DFS. In conclusion, a comprehensive molecular profile for NK-AML allows
for the identification of genetic lesions associated to different clinical outcomes and the selection
of the most appropriate and effective treatment strategies, including stem cell transplantation and
targeted therapies.
Keywords: Acute Myeloid Leukemia; molecular marker; NGS
1. Introduction
Cytogenetic analysis has proved to be crucial for the prognostic stratification of acute myeloid
leukemia (AML) patients [1]. However, nearly half of AML patients have a normal karyotype (NK). The
identification of molecular mutations has dramatically improved our knowledge of AML molecular
genetics and shed new light not only on the molecular pathogenesis of the disease but also on the
prognostic significance of each mutation and their combination in NK-AML [2,3]. NPM1 mutations are
found in approximately one third of AML and in about 50% of cases with a normal karyotype [1,4,5].
Alterations involving NPM1 often occur in combination with other genetic aberrations, which may
contribute to determining the disease evolution [3]. Moreover, about 30% of NK-AML [6] is affected
by FLT3-internal tandem duplication (ITD) resulting in the deregulation of flt3 kinase activity and
determining a worse clinical outcome, even in the presence of NPM1 mutations [7,8]. Particularly,
the evaluation of the FLT3 allelic ratio (AR) has been included in the European leukemia net (ELN)
classification to further improve risk stratification in FLT3-ITD mutated AML patients [1], even if this
remains a matter of debate [9]. The molecular characterization of AML, obtained by the application
of high throughput sequencing, has led to a better classification of this disease and its prognostic
profile [1,10]. However, most NK-AML belong to the broad intermediate prognostic subgroup in
which the most appropriate treatment strategy remains to be defined. This seems particularly relevant
when considering the new drugs targeting specific mutations [11] and the benefit potentially gained by
allogeneic transplantation as post remission consolidation treatment in these patients.
In this context, the purpose of this study was to define the association of molecular mutations with
the outcome of a cohort of 221 NK-AML patients treated according to a prospective trial comparing a
standard vs. high-dose chemotherapy regimen for remission induction (ClinicalTrials.gov identifier:
NCT00495287) [12].
2. Results
2.1. Clinical and Molecular Findings
The clinical characteristics of the 221 NK-AML patients included in this analysis are summarized
in Table 1. The median age at diagnosis was 52 years (range, 19–74 years) and the majority of them
(88%) had a de novo AML. The clinical and biological patient characteristics were generally well
balanced between the induction arms of the study (Table 1).
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Table 1. Patients characteristics according to induction treatment.
Patients Characteristics and Mutations All patients,N = 221
ICE,
N = 117
sHD,
N = 104 p
Median age, at diagnosis (range) 52.5 (19.8–74.8) 54.4 (23.6–74.8) 49.5 (19.8–72.2) 0.0324
≤60 years 166 (75.1) 81 (69.2) 85 (81.7) 0.0319
>60 years 55 (24.9) 36 (30.8) 19 (18.3)
Sex 0.1765
Female 119 (53.8) 58 (49.6) 61 (58.7)
Male 102 (46.2) 59 (50.4) 43 (41.3)
AML category 0.0463
Non de novo 26 (11.8) 9 (7.7) 17 (16.3)
De novo 195 (88.2) 108 (92.3) 87 (83.7)
ECOG PS 0.4556
0-1 201 (91) 108 (92.3) 93 (89.4)
2-3 20 (9) 9 (7.7) 11 (10.6)
Hepatomegaly 17 (7.7) 8 (6.8) 9 (8.7) 0.6130
Splenomegaly 20 (9) 9 (7.7) 11 (10.6) 0.4556
Extramedullary involvement 34 (15.4) 16 (13.7) 18 (17.3) 0.4550
WBC count (×109/L) 0.3677
≤50 155 (70.1) 79 (67.5) 76 (73.1)
>50 66 (29.9) 38 (32.5) 28 (26.9)
Hemoglobin (g/dL) 9.5 (4.3–14.1) 9.5 (5.1–14.1) 9.5 (4.3–13.9) 0.9144
Platelets(×109/L) 59 (5–815) 64 (5–815) 57.5 (8–513) 0.8752
Bone marrow blast cells, % 80 (0–100) 83 (10–100) 80 (0–100) 0.4519
Peripheral blood blasts cells, % 52 (0–100) 50 (0–100) 55.5 (0–100) 0.6909
Consolidation 0.3276
No alloHSCT 119 (67.9) 60 (59.4) 59 (66.3)
alloHSCT 71 (32.1) 41 (40.6) 30 (33.7)
FLT3 wt., NPM1 wt 90/216 (41.7) 42/112 (37.5) 48/104 (46.2) 0.1974
FLT3-ITD low ratio, NPM1 wt 6/221 (2.7) 6/117 (5.1) 0/104 (0) 0.0307
FLT3-ITD high ratio, NPM1 wt 8/221 (3.6) 4/117 (3.4) 4/104 (3.8) 1.0000
FLT3 wt, NPM1 + 66/221 (29.9) 34/117 (29.1) 32/104 (30.8) 0.7817
FLT3-ITD low ratio, NPM1 + 15/221 (6.8) 10/117 (8.5) 5/104 (4.8) 0.2700
FLT3-ITD high ratio, NPM1 + 31/221 (14) 16/117 (13.7) 15/104 (14.4) 0.8730
wt, wild type; ICE, standard idarubicin-cytarabine-etoposide chemotherapy; sHD, sequential high
dose chemotherapy.
According to trial indications [12], 71 out of 190 molecular profiled patients in first complete
remission (CR) underwent alloHSCT (Figure 1).
The NGS analysis of the 221 patients identified a total of 738 mutations, including non-synonymous
point mutations (missense (n = 334) and nonsense (n = 42)), insertions or deletions (indels) (in frame (n
= 112) or causing a frameshift (n = 226)), and splicing sites mutations (n = 24). The number of molecular
alterations per patient ranged from 0 to a maximum of 15, with a median of 3. Only five patients
did not present mutations detectable by the applied gene panel. The mutation frequencies according
to induction treatment are reported in Figure 2, whereas the number of alterations per patient and
per gene are represented in Figure 3. Moreover, we measured the association between mutations in
different genes, considering genes in pairs (Figure 4).
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Figure 4. Pairwise association among gene mutations. The odds ratio of the association is color coded:
blue colors indicate a negative association while red colors indicate a positive association. In addition,
differential green intensity represent a different co-occurrence of mutations in terms of number of
patients. Triangle indicates a group of genes which frequently co-mutate in NPM1 wild-type AML.
CEBPA2 and CEBPA1 indicate the presence of double or single mutation, respectively.
As expected, the most frequently mutated gene in our cohort of patients was NPM1, followed by
DNMT3A and FLT3. We noticed that DNMT3A, FLT3, IDH1, PTPN11, and RAD21 mutations were more
common in the NPM1 mutated patients (p < 0.05). In particular, IDH1 R132H mutation was strictly
associated with NPM1 mutation and mutually exclusive with RUNX1 and ASXL1 while the R132C
was not [13]. Alterations involving the IDH2 gene in specific amino-acids showed a different behavior
regarding co-occurrence with other genes lesions. Particularly, IDH2 R140 mutation was associated
with the presence of NPM1 alteration and rarely with RUNX1 mutations, while the amino-acid changes
involving R172 presented the opposite combinations [14]. As expected, RUNX1 mutations often
co-occurred with alterations in ASXL1, BCOR, SF3B1, SRSF2, STAG2, NRAS, and KMT2A-PTD [15],
and within this latter group of genes, pathologic variants were also frequently present in combination
(Figure 4). BCOR mutations were virtually mutually exclusive with NPM1 mutations while associated
with RUNX1 alterations [16]. Lastly, TP53 mutations were revealed only in one NK-AML patient as
solely identified genetic aberration (Figure 3). Interestingly, this patient harbored two point mutations
probably affecting two different alleles, as commonly described for tumor suppressor genes.
2.2. Impact of Clinical and Molecular Profiling on CR Achievement
By univariate nalysis, (Table 2) age, Eastern Cooperative Oncology Group (ECOG) performance
status (PS), de novo AML nature and gene mutation profile at diagnosis had an impact on
CR achievement.
In particular, achievement of CR was negatively affected by the presence of molecular alterations
in TET2, ASXL1 and SRSF2 genes. On the contrary, the group of patients characterized by the presence
of an NPM1 gene mutation in the absence of FLT3-ITD showed a significantly higher probability to
achieve CR (Table 2). The presence of a double mutation in CEBPA gene was associated with a favorable
hazard ratio (HR) for CR achievement. By multivariate analysis, the negative effect of the presence of
an altered SRSF2 gene on CR achievement was confirmed (Table 3).
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Table 2. Univariate analysis on patients outcome.
Patients Characteristics
CR OS DFS
HR p HR p HR p
HDS 0.94 (0.44–2.03) 0.8731 0.86 (0.59–1.26) 0.4318 0.82 (0.54–1.23) 0.3276
HSCT - - 0.31 (0.18–0.51) 0.0000 0.29 (0.17–0.48) <0.0001
Age > 60 0.21 (0.09–0.45) 0.0001 2.67 (1.81–3.95) 0.0000 1.92 (1.22–3.02) 0.0047
Sex male 1.67 (0.77–3.79) 0.2019 0.95 (0.65–1.39) 0.7982 1.06 (0.7–1.58) 0.7901
De novo 2.62 (0.94–6.69) 0.0503 0.73 (0.42–1.27) 0.2665 0.76 (0.41–1.43) 0.3975
ECOG PS 2–3 0.25 (0.09–0.73) 0.0076 2.24 (1.25–4.01) 0.0065 1.06 (0.46–2.43) 0.886
WBC count > 50 0.74 (0.34–1.7) 0.4621 1.61 (1.09–2.39) 0.0179 1.37 (0.89–2.12) 0.1533
NPM1 1.76 (0.82–3.92) 0.1541 0.71 (0.48–1.04) 0.0780 0.76 (0.51–1.14) 0.1864
VAF ≤ 0.4 2.18 (0.87–6.27) 0.1162 0.67 (0.42–1.05) 0.0785 0.89 (0.57–1.39) 0.6075
VAF > 0.4 1.3 (0.5–3.81) 0.6031 0.8 (0.48–1.33) 0.3924 0.59 (0.33–1.08) 0.0866
FLT3-ITD 0.79 (0.34–1.93) 0.5811 2.23 (1.5–3.32) 0.0001 2.18 (1.43–3.33) 0.0003
FLT3-ITD low 0.95 (0.29–4.29) 0.9380 1.67 (0.9–3.08) 0.1032 1.55 (0.8–3.04) 0.1966
FLT3-ITD high 0.87 (0.34–2.51) 0.7813 2.43 (1.56–3.78) 0.0001 2.6 (1.62–4.18) 0.0001
DNMT3A 1.01 (0.47–2.25) 0.9799 1.25 (0.85–1.83) 0.2606 1.49 (0.99–2.23) 0.0553
TET2 0.23 (0.1–0.54) 0.0006 1.38 (0.85–2.24) 0.1926 0.94 (0.5–1.76) 0.8357
RUNX1 0.42 (0.17–1.08) 0.0590 2.25 (1.43–3.55) 0.0005 1.95 (1.15–3.3) 0.0132
IDH2 0.68 (0.25–2.17) 0.4754 0.77 (0.4–1.47) 0.4247 1.05 (0.56–1.97) 0.8732
CEBPA2 * 3.37 (0.66–61.69) 0.2450 0.26 (0.1–0.71) 0.0088 0.21 (0.06–0.65) 0.007
FLT3_PM 1.57 (0.42–10.17) 0.5605 0.45 (0.2–1.04) 0.0608 0.38 (0.16–0.94) 0.0371
IDH1 0.98 (0.3–4.36) 0.9714 0.95 (0.51–1.78) 0.8781 0.98 (0.51–1.89) 0.9575
ASXL1 0.25 (0.09–0.73) 0.0076 1.54 (0.86–2.76) 0.1434 1.3 (0.63–2.68) 0.4827
CEBPA1 * 2.32 (0.44–42.85) 0.4243 0.56 (0.23–1.39) 0.2133 0.63 (0.25–1.55) 0.3141
PTPN11 2.95 (0.57–54.09) 0.3022 0.46 (0.19–1.13) 0.0908 0.58 (0.26–1.33) 0.2018
SRSF2 0.12 (0.04–0.34) 0.0001 1.43 (0.77–2.67) 0.2596 0.8 (0.29–2.17) 0.6553
NRAS 0.74 (0.22–3.37) 0.6557 1.46 (0.78–2.72) 0.2387 1.31 (0.64–2.71) 0.4607
KMT2A-PTD 2.42 (0.46–44.57) 0.4027 1.34 (0.67–2.67) 0.4037 1.44 (0.72–2.88) 0.298
STAG2 0.35 (0.1–1.36) 0.0990 1.33 (0.61–2.88) 0.4712 1.3 (0.52–3.23) 0.5691
BCOR 1.95 (0.36–36.43) 0.5310 1.58 (0.73–3.44) 0.2456 1.52 (0.66–3.51) 0.3258
KRAS 1.84 (0.34–34.31) 0.5648 0.81 (0.33–2) 0.6546 1.1 (0.48–2.52) 0.8178
WT1 1.84 (0.34–34.31) 0.5648 0.8 (0.32–1.95) 0.6185 0.75 (0.28–2.04) 0.5736
GATA2 >99.99 (0–NA) 0.9894 0 (0–Inf) 0.9953 0 (0–Inf) 0.9954
SF3B1 1.32 (0.23–24.91) 0.7976 1.42 (0.66–3.06) 0.3689 1.8 (0.83–3.9) 0.1348
U2AF1 1.32 (0.23–24.91) 0.7976 2.69 (1.3–5.55) 0.0075 3.57 (1.64–7.74) 0.0013
FLT3wt, NPM1 wt 0.58 (0.26–1.28) 0.1744 1.12 (0.76–1.65) 0.5682 1.08 (0.71–1.63) 0.726
FLT3-ITD low ratio,
NPM1 wt 0.81 (0.12–15.82) 0.8505 1.55 (0.57–4.23) 0.388 1.3 (0.41–4.1) 0.6572
FLT3-ITD high ratio,
NPM1 wt >99.99 (0–NA) 0.9861 2.09 (0.97–4.49) 0.0602 2.47 (1.14–5.34) 0.0214
FLT3wt, NPM1 + 3.27 (1.21–11.42) 0.0336 0.35 (0.21–0.59) 0.0001 0.44 (0.27–0.71) 0.0009
FLT3-ITD low ratio,
NPM1 + 1.06 (0.28–7.03) 0.9361 1.27 (0.62–2.62) 0.5089 1.25 (0.58–2.7) 0.5683
FLT3-ITD high ratio,
NPM1 + 0.63 (0.25–1.83) 0.3602 2.15 (1.33–3.47) 0.0017 2.21 (1.31–3.75) 0.0031
* CEBPA2 and CEBPA1 indicate the presence of double or single mutation, respectively.
The probability to reach CR was not different according to the treatment allocation when a forest
plot analysis was applied to each mutation (Figure S1).
2.3. Impact of Clinical and Molecular Characteristics on Survival
Survival analysis showed that age, ECOG PS and white blood counts influenced the clinical
outcome of NK-AML (Table 2). Mutations of FLT3 (FLT3-ITD), RUNX1, and U2AF1 were associated
with a worse OS and DFS (p < 0.05) while double alterations involving CEBPA gene proved to have a
favorable impact on clinical outcome, both in terms of OS and DFS (p < 0.05). Patients with NPM1 gene
mutations but negative for FLT3-ITD had a better OS and DFS (p = 0.0001 and 0.0009, respectively)
(Table 2 and Figure S2). This survival advantage was particularly evident in patients randomized to
high-dose chemotherapy during the induction phase (Figure S3). Conversely, the presence of NPM1
gene mutations did not improve the clinical outcome of patients also bearing FLT3-ITD alteration. A
gradient effect on survival was documented when FLT3-ITD positive patients were classified according
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to ELN guidelines 2017 as low-AR-FLT3-ITD (allelic ratio, AR < 0.5) or high-AR (AR ≥ 0.5) (Table 2,
Figure 5).
Table 3. Multivariable analysis for patients characteristics, treatments and mutations in the
complete cohort.
Patients Characteristics
CR OS DFS
HR p HR p HR p
HSCT - - 0.34 (0.19–0.60) 0.0002 0.34 (0.19–0.60) <0.0001
Age > 60 0.43 (0.15–1.22) 0.1049 1.37 (0.78–2.40) 0.2661 0.89 (0.51–1.55) 0.6864
De novo 2.17 (0.55–7.76) 0.2460 - - - -
ECOG PS 2–3 0.26 (0.07–1) 0.0398 1.09 (0.42–2.85) 0.8559 - -
WBC count > 50 - - 1.20 (0.67–2.14) 0.5456 1.07 (0.63–1.82) 0.8023
NPM1 1.06 (0.33–3.3) 0.9239 0.58 (0.32–1.06) 0.0761 0.49 (0.28–0.88) 0.0163
FLT3-ITD - - 2.76 (1.56–4.91) 0.0005 2.81 (1.66–4.73) 0.0001
DNMT3A - - - - 1.62 (0.95–2.77) 0.0772
TET2 0.4 (0.13–1.24) 0.1048 0.74 (0.33–1.66) 0.4715 - -
RUNX1 0.54 (0.15–2.03) 0.3501 1.25 (0.60–2.61) 0.5567 0.89 (0.43–1.87) 0.7638
CEBPA2 * - - 0.20 (0.06–0.68) 0.0097 0.17 (0.05–0.57) 0.0040
FLT3_PM - - 0.65 (0.23–1.89) 0.4325 0.65 (0.25–1.67) 0.3731
ASXL1 0.87 (0.19–4.63) 0.8628 0.42 (0.16–1.08) 0.0713 - -
PTPN11 - - 0.60 (0.21–1.73) 0.3450 - -
SRSF2 0.24 (0.06–0.95) 0.0376 - - - -
STAG2 0.97 (0.18–6.65) 0.9715 - - - -
SF3B1 - - - - 1.02 (0.42–2.45) 0.9663
U2AF1 - - 4.19 (1.72–10.23) 0.0016 5.54 (2.25–13.66) 0.0002
* CEBPA2 indicates the presence of a double mutation.
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We also verified if the allelic burden calculated for NPM1 mutations (variant allelic fraction, VAF
≤ 0.4 or > 0.4) could have an impact on outcome as recently reported [17] but we did not observe
any correlation between NPM1 VAF and clinical outcome in our cohort of patients. By multivariate
analysis (Table 3), the positive effect on survival of an aberrant NPM1 and a double mutated CEBPA
was confirmed. In addition, the negative effect on survival related to FLT3-ITD as well as mutations
involving U2AF1 gene remained statistically significant also by multivariate analysis.
The univariate analysis showed that the presence of FLT3-ITD abolished the prognostic impact
of any other identified mutation. By contrast, in patients with no NPM1 or FLT3-ITD mutations, the
presence of DNMT3A, TET2, RUNX1, NRAS, and U2AF1 negatively affected survival (Table 4).
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Table 4. Univariate analysis for patients characteristics, treatments and mutations in patients lacking
both FLT3-ITD and NPM1 alterations (n = 90 and n = 75 achieving CR).
Patients Characteristics
CR n = 90 OS n = 90 DFS n = 75
HR p HR p HR p
HDS 0.51 (0.15–1.59) 0.2622 1.29 (0.72–2.32) 0.3877 1.05 (0.56–1.98) 0.8837
HSCT - - 0.43 (0.21–0.89) 0.0229 0.42 (0.2–0.88) 0.0225
Age > 60 0.51 (0.16–1.69) 0.2524 2.28 (1.26–4.15) 0.0068 2.63 (1.35–5.11) 0.0043
Sex male 2.38 (0.78–7.77) 0.1336 0.63 (0.35–1.13) 0.1194 0.86 (0.45–1.64) 0.6537
De novo 2.38 (0.65–7.98) 0.1657 0.63 (0.33–1.22) 0.1729 0.58 (0.27–1.23) 0.1569
ECOG PS 2–3 1 (0.15–19.93) 1.0000 2.66 (0.95–7.47) 0.0635 2 (0.61–6.53) 0.2504
WBC count > 50 1.22 (0.19–23.93) 0.8605 0.54 (0.13–2.24) 0.3955 0.28 (0.04–2.03) 0.2066
DNMT3A 0.48 (0.12–2.41) 0.3219 2.77 (1.32–5.8) 0.0068 3.83 (1.67–8.76) 0.0015
TET2 0.21 (0.05–0.81) 0.0195 2.26 (1.09–4.71) 0.0286 2.33 (0.9–5.99) 0.0797
RUNX1 0.41 (0.13–1.37) 0.1323 2.36 (1.28–4.35) 0.0060 1.96 (0.97–3.96) 0.0608
IDH2 0.52 (0.15–2.13) 0.3297 1.03 (0.46–2.3) 0.9439 1.56 (0.68–3.54) 0.2909
CEBPA2 * 4.5 (0.81–84.34) 0.1598 0.16 (0.05–0.53) 0.0026 0.12 (0.03–0.5) 0.0035
ASXL1 0.27 (0.08–1.03) 0.0466 1.26 (0.59–2.7) 0.5564 1.12 (0.44–2.86) 0.8194
CEBPA1 * >99.99 (0–NA) 0.9934 0.45 (0.14–1.45) 0.1801 0.72 (0.25–2.03) 0.5315
SRSF2 0.08 (0.02–0.31) 0.0003 1.33 (0.59–2.98) 0.4889 0.7 (0.17–2.93) 0.6305
NRAS 0.57 (0.11–4.14) 0.5123 2.88 (1.28–6.48) 0.0105 2.9 (1.13–7.48) 0.0272
KMT2A-PTD 3.5 (0.62–65.89) 0.2437 1.05 (0.49–2.26) 0.8960 1.22 (0.56–2.66) 0.6168
STAG2 0.79 (0.17–5.67) 0.7783 1.16 (0.45–2.98) 0.7603 1.57 (0.6–4.09) 0.3593
BCOR >99.99 (0–NA) 0.9908 1.31 (0.46–3.71) 0.6128 1.36 (0.48–3.9) 0.5639
KRAS >99.99 (0–NA) 0.9914 0.61 (0.08–4.44) 0.6276 0.6 (0.08–4.37) 0.6138
WT1 >99.99 (0–NA) 0.9903 0.58 (0.18–1.86) 0.3584 0.6 (0.18–1.96) 0.3983
GATA2 >99.99 (0–NA) 0.9937 0 (0–Inf) 0.9973 0 (0–99.99) 0.9973
SF3B1 1.44 (0.23–28.05) 0.7417 1.4 (0.59–3.3) 0.4479 1.77 (0.74–4.26) 0.2010
U2AF1 1.67 (0.27–32.28) 0.6406 3.03 (1.4–6.58) 0.0049 3.89 (1.69–8.93) 0.0014
* CEBPA2 and CEBPA1 indicate the presence of double or single mutation, respectively.
In this subgroup, the unfavorable prognostic effect of U2AF1 mutations on survival remained
significant also by multivariate analysis. The presence of a RUNX1 mutation was associated with an
unfavorable, despite not statistically significant, HR for survival (Table 5).
Table 5. Multivariate analysis for patients characteristics, treatments and mutations in FLT3 wt and
NPM1 wt patients.
Patients Characteristics
CR OS DFS
HR (95% CI) p HR (95% CI) p HR (95% CI) p
HSCT - - 0.42 (0.16–1.09) 0.0744 0.24 (0.09–0.62) 0.0032
Age > 60 - - 1.02 (0.43–2.41) 0.9624 1.12 (0.51–2.45) 0.7778
Sex male 2.57 (0.66–11.53) 0.1846 0.77 (0.33–1.78) 0.5462 - -
De novo 0.65 (0.11–2.96) 0.5985 0.88 (0.36–2.16) 0.7753 1.29 (0.50–3.33) 0.5997
ECOG PS 2–3 - - 2.24 (0.54–9.31) 0.2681 - -
DNMT3A - - 2.58 (0.80–8.28) 0.1105 3.57 (1.07–11.89) 0.0383
TET2 0.15 (0.02–0.94) 0.0387 2.32 (0.70–7.63) 0.1670 1.93 (0.62–6.03) 0.2600
RUNX1 0.44 (0.1–1.99) 0.2747 2.20 (0.93–5.24) 0.0741 1.93 (0.83–4.50) 0.1277
CEBPA2 * 3.93 (0.47–98.06) 0.2806 0.20 (0.04–0.92) 0.0387 0.13 (0.03–0.58) 0.0070
ASXL1 1.38 (0.24–11.14) 0.7367 - - - -
NRAS - - 1.21 (0.38–3.87) 0.7457 1.05 (0.34–3.29) 0.9284
SRSF2 0.08 (0.01–0.5) 0.0093 - - - -
U2AF1 - - 3.39 (1.16–9.92) 0.0260 3.81 (1.35–10.78) 0.0117
* CEBPA2 indicates the presence of a double mutation.
2.4. Impact of alloHSCT by Molecular Lesions
The 22 FLT3-ITD positive patients who could proceed to alloHSCT had a survival probability
similar to FLT3-ITD negative patients. The transplant outcome was not different when comparing high
and low-AR-FLT3-ITD subgroups both in terms of OS (Figure 6) and DFS. The OS of FLT3-ITD positive
patients, no matter if NPM1 negative or positive, who did not receive alloHSCT for whatever reason
showed quite a poor outcome (Figure 6B, p < 0.00001). The limited number of patients precluded the
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possibility to evaluate the ability of alloHSCT to modify the adverse outcome associated with other
molecular alterations.
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3. Discussion
In this study, we provide an accurate molecular characterization of 221 NK-AML patients included
in a prospective clinical trial comparing the standard ICE induction chemotherapy to the high-dose
regimen. By applying an NGS high throughput solution to sequence myeloid neoplasms related genes,
we were able to identify at least one mutation in the great majority of patients (98%). Frequencies and
co-occurrence of mutations are consistent with previous observations [3,14]. Our data confirm that the
identification of CEBPA, NPM1, and FLT3-ITD mutations, alone or in combination, remains crucial
to define patient subgroups with different prognoses. Double mutation in CEBPA gene identifies a
subgroup of patient characterized by a particularly favorable outcome. On the contrary, FLT3-ITD
mutations represent the most relevant marker of unfavorable prognosis in this setting, no matter
the presence of NPM1 or other gene mutations. We observed a gradient effect played by FLT3-ITD
allele burden on survival since, the low-AR-FLT3-ITD was still associated to a negative outcome.
This correlation was not statistically significant probably due to the sample size of low-AR-FLT3-ITD
subgroups (with or without mutant NPM1) which is relatively low. This observation is in line with
other studies [9,18] and represents an open challenge as to the choice of the post-remission strategies.
Within the limit of a modest number of patients so far analyzed, our results suggest that alloHSCT
can abolish the adverse effect due to the FLT3-ITD mutation. For these reasons, at our institution,
alloHSCT remains the preferred post remission option for patients with low-AR-FLT3-ITD. The role
of innovative FLT3 inhibitors, either to improve the transplant outcome or to avoid it, will perhaps
modify the therapeutic scenario of this AML subgroup [19–21]. The FLT3-ITD mutation exerts its
negative influence also in NPM1 mutated patients. This observation supports the paradigm of how the
presence of co-occurring mutations can modify the effect of a single mutation on the prognosis [22] and
demonstrates the importance of refining molecular characterization of AML at disease presentation.
In patients with no mutations of both FLT3-ITD and NPM1, additional mutations in other
leukemia-related genes proved to influence disease evolution. Therefore, the identification of specific
mutations in this subgroup is mandatory to predict the clinical outcome and to select the most
appropriate treatment approach. We found that molecular lesions in TET2, SRSF2, and U2AF1 were
associated with negative outcomes. Our data are in line with recent studies showing that TET2
mutations and older age are independent prognostic factor in AML [23]. The U2AF1 adverse prognostic
impact on survival has been already reported in a limited AML cohort [24]. To the best of our
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knowledge, the data on the impact of SRSF2 mutations on CR achievement were not previously
reported in a cohort of patients with AML.
For the few patients (2%) with no evidence of DNA mutations, sequencing of a wider genome
region, including regulatory and intronic sequences, and/or the use of an integrate analysis including
other approach as comparative genomic hybridization arrays might identify rarer AML related genetic
abnormalities and provide useful information for clinical decision making [25].
4. Patients and Methods
Out of 574 newly diagnosed AML patients enrolled into the NILG-AML 02/06 clinical trial, 270
subjects showed a normal karyotype. Molecular profile was performed on a total of 221 NK-AML with
available diagnostic samples. Patients were affected by a de novo AML or by an AML secondary to
chemo-radiotherapy or to a myelodysplastic/myeloproliferative syndrome (Table 1). This protocol was
a randomized trial comparing ICE (idarubicin-cytarabine-etoposide) with sequential high dose (HD)
chemotherapy in untreated patients with the intent to improve the early remission rate and to evaluate
the impact on survival [12]. The trial protocol has been approved by the institutional review boards at
each of the participating center (Comitato etico della provincia di Bergamo (CE150180), Comitato Etico
Area Vasta Centro (CE150071), Comitato Etico città della salute e della scienza (CE150115), Comitato
Etico Brianza (CE150179), Comitato Etico Interaziendale A.S.O. SS. Antonio e Biagio e C.Arrigo di
Alessandria (CE150105), Comitato Etico di Brescia (CE150186), Comitato etico per la sperimentazione
clinica - Comprensorio di Bolzano (CE150099), Comitato Etico Interaziendale Aso S.Croce E Carle
(CE150123), CESC della Provincia di Venezia e IRCSS San Camillo(CE150073), Comitato Etico Val
Padana (CE150177), Comitato Etico dell’IRCCS San Raffaele (CE150050), Comitato Etico Indipendente
Istituto Clinico Humanitas (CE150081), Comitato Etico dell’Insubria (CE150185), Comitato Etico
Indipendente della Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (CE150053) and
Comitato Etico Milano Area 2 (CE150176)).Informed consents for inclusion in the trial and for genetic
analysis were obtained from all patients. Genomic DNA was isolated from mononuclear cells obtained
from bone marrow or peripheral blood at diagnosis, containing at least 20% blasts. In the analysis of
FLT3-ITD and D835 point mutations, KTM2A-PTD, NPM1, and CEBPA alterations were prospectively
obtained with standard approaches (PCR analysis, enzymatic digestion, Sanger sequencing). In
addition, we estimated the mutant to wild-type allelic ratio (AR) of FLT3-ITD using fragment length
analysis technique [26]. Subsequently, on the same prospectively collected diagnostic samples, we
obtained a more complete molecular profile by next generation sequencing (NGS) of targeted regions
of a wide selection of myeloid neoplasms related genes. Two commercial NGS kits were applied
to prepare DNA libraries for sequencing: Trusight Myeloid panel (Illumina, San Diego, CA, USA)
and Sophia Myeloid Solution (SOPHiA GENETICS, SA, CH) investigating 54 and 30 gene regions,
respectively (Table S1). The libraries were sequenced and demultiplexed on a MiSeq or MiniSeq
instruments (Illumina, San Diego, CA). The median coverage was 6373 reads (range 44166–103) with
92% sequenced regions with > 500 and 87% with > 1000 reads. The limit of detection (LOD) for a
reliable variant calling was down to 5% variant allele frequency (VAF), as recommended by both
the producers. Frameshift and nonsense variants were always considered as relevant mutations.
Single nucleotide variants were retained in the absence of description as genetic polymorphism into
public databases of human polymorphisms (NCBI dbSNP (http://www.ncbi.nlm.nih.gov/snp; Build
137) and ExAC (http://exac.broadinstitute.org/)). Functional prediction for missense variants was
derived from SIFT 1.03 (http://sift.jcvi.org) and PolyPhen2.0 (http://genetics.bwh.harvard.edu/pph2).
For alterations of splicing sites and splicing related regions, we used the Human Splicing tool
(Human Splicing Finder) to predict the effect on the splicing process. Finally, the description of
other cancer specimens in terms of the identified mutations was checked against COSMIC database
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic).
The clinical endpoints of the study were defined according to standard criteria [27]. Overall
survival (OS) was defined as the probability of survival irrespective of disease state at any point in
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time from diagnosis. Patients alive at their last follow-up were censored. Disease free survival (DFS)
was measured from the time of first CR until relapse or death. Baseline continuous characteristics
were presented as median with range and compared using the Mann–Whitney U test. Categorical
variables were reported with absolute and percentage frequencies and compared with Chi-squared test
or Fisher’s exact test. OS and DFS were estimated by the Kaplan–Meier method and any differences
were evaluated with a log-rank test. Cox models were used to estimate hazard ratios with 95%
confidence intervals (CI) in univariate and multivariable analysis on survival outcomes. In this context,
allogeneic hematologic stem cell transplantation (alloHSCT) was considered as a time-dependent event;
Mantel–Byar tests and Simon–Makuch plots were used. In multivariable models, only factors with a p
value < 0.2 in a corresponding univariate model were included. All reported p values are two-sided
and a 5% significance level was set. All analyses were performed with R software, version 3.5.0.
5. Conclusions
In NK-AML, the accurate and in-depth molecular characterization did not lead to the recognition
of a mutational profile associated with a different rate of response following an intensified induction
chemotherapy program. No matter the induction chemotherapy, we identified mutations which
are associated with different outcomes and which help to select the most appropriate consolidation
strategies, namely alloHSCT. Finally, the identification of mutations that represent a potential treatment
target for new drugs is now mandatory for offering patients new chemotherapy free therapeutic options.
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